Multiple sclerosis—a quiet revolution

[1]  M. Daly,et al.  Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.

[2]  Steven H. Kleinstein,et al.  B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes , 2014, Science Translational Medicine.

[3]  T. Lazzarotto,et al.  Recommendations for Fingolimod Treated Patients Vacinated for Varicella Zoster Virus. (P7.217) , 2014 .

[4]  Carlo Pozzilli,et al.  Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis , 2014, Multiple sclerosis.

[5]  À. Rovira,et al.  Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event , 2014, PloS one.

[6]  C. Guttmann,et al.  Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus , 2013, Neurology.

[7]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[8]  L. Fugger,et al.  A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis. , 2013, Pharmacogenomics.

[9]  D. Goodin,et al.  Mortality in patients with multiple sclerosis , 2013, Neurology.

[10]  Gavin Giovannoni,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[11]  M. Calabrese,et al.  Low degree of cortical pathology is associated with benign course of multiple sclerosis , 2013, Multiple sclerosis.

[12]  M. Rovaris.  Faculty Opinions recommendation of Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. , 2013 .

[13]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[14]  B. Trapp,et al.  Cortical remyelination: A new target for repair therapies in multiple sclerosis , 2012, Annals of neurology.

[15]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[16]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[17]  J. Mesirov,et al.  An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease Activity , 2012, Science Translational Medicine.

[18]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[19]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[20]  J. Correale,et al.  Benign Multiple Sclerosis: Does it exist? , 2012, Current Neurology and Neuroscience Reports.

[21]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[22]  D. Goodin,et al.  Survival in MS , 2012, Neurology.

[23]  Ludwig Kappos,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[24]  David H. Miller,et al.  Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study , 2012, Multiple sclerosis.

[25]  A. Giorgio,et al.  Association of MRI metrics and cognitive impairment in radiologically isolated syndromes , 2012, Neurology.

[26]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[27]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[28]  Xin Chen,et al.  Contrasting effects of TNF and anti‐TNF on the activation of effector T cells and regulatory T cells in autoimmunity , 2011, FEBS letters.

[29]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[30]  K. Guckian,et al.  Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo , 2011, Molecular and Cellular Neuroscience.

[31]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[32]  R. Spain,et al.  Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors , 2011, Multiple sclerosis.

[33]  M. Krumbholz,et al.  Humoral autoimmunity in multiple sclerosis , 2011, Journal of the Neurological Sciences.

[34]  J. Parisi,et al.  A case of multiple sclerosis presenting with inflammatory cortical demyelination , 2011, Neurology.

[35]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system , 2011, Neurology.

[36]  D. Goodin,et al.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome , 2011, Neurology.

[37]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[38]  Xavier Montalban,et al.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.

[39]  A. Menter,et al.  The use of ustekinumab in autoimmune disease , 2010, Expert opinion on biological therapy.

[40]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[41]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[42]  R. Ransohoff.  PML risk and natalizumab: more questions than answers , 2010, The Lancet Neurology.

[43]  X. Montalban,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[44]  C. Pozzilli,et al.  Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis , 2009, Annals of neurology.

[45]  A Giorgio,et al.  Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis , 2009, Neurology.

[46]  Brandon A Brown.  Natalizumab in the treatment of multiple sclerosis , 2009, Therapeutics and clinical risk management.

[47]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[48]  M. Rovaris,et al.  Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study , 2009, Multiple sclerosis.

[49]  Ludwig Kappos,et al.  Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[50]  K. Selmaj,et al.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.

[51]  N. Richert,et al.  Faculty Opinions recommendation of Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. , 2008 .

[52]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[53]  G. Comi,et al.  Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[54]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[55]  H. J. Kim,et al.  Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells , 2007, Glia.

[56]  S. Gabriel,et al.  Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.

[57]  R. Ransohoff,et al.  Natalizumab for multiple sclerosis. , 2007, The New England journal of medicine.

[58]  Christine Stadelmann,et al.  Extensive Cortical Remyelination in Patients with Chronic Multiple Sclerosis , 2007, Brain pathology.

[59]  M. Trojano,et al.  New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .

[60]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[61]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[62]  B. Engelhardt,et al.  Dysferlin Is a New Marker for Leaky Brain Blood Vessels in Multiple Sclerosis , 2006, Journal of neuropathology and experimental neurology.

[63]  R. Ransohoff.  A mighty mouse: building a better model of multiple sclerosis. , 2006, The Journal of clinical investigation.

[64]  I. Koralnik.  Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? , 2006, Annals of neurology.

[65]  F. Barkhof,et al.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.

[66]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[67]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[68]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[69]  B. Weinshenker,et al.  Natural history of multiple sclerosis. , 2005, Neurologic clinics.

[70]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[72]  R. Kastelein,et al.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain , 2003, Nature.

[73]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[74]  R. Ransohoff,et al.  Chemokine expression in GKO mice (lacking interferon-gamma) with experimental autoimmune encephalomyelitis. , 1999, Journal of neurovirology.

[75]  B. M. Lanning,et al.  A longitudinal magnetic resonance imaging study of the brain in survivors of childhood acute lymphoblastic leukemia , 1998, Cancer.

[76]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.

[77]  T. Owens,et al.  Interferon‐γ confers resistance to experimental allergic encephalomyelitis , 1996, European journal of immunology.

[78]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[79]  D. Li,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[80]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[81]  R. Fishman.  Cerebrospinal Fluid in Diseases of the Nervous System , 1992 .

[82]  R. Ransohoff,et al.  Pharmacotherapy of multiple sclerosis: current status. , 1992, Cleveland Clinic journal of medicine.

[83]  A. Sadovnick,et al.  Epidemiology and genetics of multiple sclerosis. , 1992, Current opinion in neurology and neurosurgery.

[84]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.

[85]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[86]  Christopher Anderson,et al.  More questions than answers , 1991, Nature.

[87]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[88]  神部 恒子.  MS〔Multiple Sclerosis〕虹の会・東北 , 1987 .

[89]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[90]  H. Weiner,et al.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.

[91]  T. Rivers,et al.  OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS , 1933, The Journal of experimental medicine.

[92]  Chris Cotsapas,et al.  Immune-mediated disease genetics: the shared basis of pathogenesis. , 2013, Trends in immunology.

[93]  E. Lehman,et al.  JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis , 2013 .

[94]  E. Waubant,et al.  Humoral-Targeted Immunotherapies in Multiple Sclerosis , 2012, Neurotherapeutics.

[95]  F. Lublin,et al.  Interferon Beta and Glatiramer Acetate Therapy , 2012, Neurotherapeutics.

[96]  R. Hohlfeld,et al.  Therapeutic Approaches in Multiple Sclerosis , 2012, BioDrugs.

[97]  R. Hohlfeld,et al.  Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. , 2002, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[98]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.

[99]  J. Dawson,et al.  XVIII.–The Histology of Disseminated Sclerosis , 1916, Transactions of the Royal Society of Edinburgh.

[100]  G. A. Moore,et al.  randomised double blind placebo controlled trial , 2022 .